Syneos Health Introduces FSP 360
Syneos Health, the fully integrated biopharmaceutical solutions organization, introduced FSP 360, an evolved FSP model that provides access to the industry’s to a broad range of traditional and non-traditional FSP capabilities.
“As customers look to consolidate outsourced clinical solutions, traditional static FSP models no longer meet their unique scientific and operational demands,” said Paul Colvin, President, Syneos Health Clinical Solutions.
FSP 360 provides a range of capabilities through combining traditional service functions including monitoring, project management, safety/pharmacovigilance and data services, with non-traditional capabilities including investigator payments, eTMF, site contracts, feasibility and study start up. Engagements are scalable based on where a customer is in their outsourcing evolution.
To learn more www.syneoshealth.com
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
